Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

Ann E. McCullough, Patrizia Dell'Orto, Monica M. Reinholz, Richard D. Gelber, Amylou Dueck, Leila Russo, Robert Brian Jenkins, Stefania Andrighetto, Beiyun Chen, Christian Jackisch, Michael Untch, Edith A. Perez, Martine J. Piccart-Gebhart, Giuseppe Viale

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status. Before randomization in the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN, and Scottsdale, AZ) for North America and by the European Institute of Oncology (IEO; Milan, Italy) for the rest of world (except China). Discordance rates (local vs. central review) differed between Mayo and IEO. Among locally HER2-positive cases, 5.8 % (Mayo) and 14.5 % (IEO) were centrally HER2 negative. Among locally ER-positive cases, 16.2 % (Mayo) and 4.2 % (IEO) were centrally ER-negative. Among locally ER-negative cases, 3.4 % (Mayo) and 21.4 % (IEO) were centrally ER-positive. We, therefore, performed a ring study to identify features contributing to these differing discordance rates. Mayo and IEO exchanged slides for 25 HER2 and 35 ER locally/centrally discordant cases. Both laboratories performed IHC and FISH for HER2 using the HercepTest® and PathVysion HER2 DNA probe kit/HER2/centromere 17 probe mixture. IHC for ER was tested centrally using the monoclonal ER 1D5 antibody (Mayo) or the DAKO cocktail of ER 1D5 and 2.123 antibodies (IEO). Mayo and IEO confirmed the central HER2-negative result in 100 % of 25 cases. Mayo and IEO confirmed the central ER result in 29 (85 %) of 34 evaluable cases. The five Mayo-negative/IEO-positive cases were ER-positive when retested at Mayo using the DAKO ER cocktail. In this ring study, ALTTO ineligibility did not change when HER2 testing was performed by either IEO or Mayo central laboratories. However, a dual antibody ER assay had fewer false-negative test results than an assay with a single antibody, and there was more discordance between the two ER reagents than has been previously reported. Using even slightly different assay methods yielded different results, even between experienced central laboratories.

Original languageEnglish (US)
Pages (from-to)485-492
Number of pages8
JournalBreast Cancer Research and Treatment
Volume143
Issue number3
DOIs
StatePublished - Feb 2014

Fingerprint

Estrogen Receptors
Pathology
Breast Neoplasms
Antibodies
human ERBB2 protein
Trastuzumab
lapatinib
Centromere
DNA Probes
Random Allocation
North America
Italy
China

Keywords

  • Breast cancer
  • Central laboratory review
  • Estrogen receptor testing
  • HER2 testing
  • Local versus central laboratory concordance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Central pathology laboratory review of HER2 and ER in early breast cancer : An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. / McCullough, Ann E.; Dell'Orto, Patrizia; Reinholz, Monica M.; Gelber, Richard D.; Dueck, Amylou; Russo, Leila; Jenkins, Robert Brian; Andrighetto, Stefania; Chen, Beiyun; Jackisch, Christian; Untch, Michael; Perez, Edith A.; Piccart-Gebhart, Martine J.; Viale, Giuseppe.

In: Breast Cancer Research and Treatment, Vol. 143, No. 3, 02.2014, p. 485-492.

Research output: Contribution to journalArticle

McCullough, AE, Dell'Orto, P, Reinholz, MM, Gelber, RD, Dueck, A, Russo, L, Jenkins, RB, Andrighetto, S, Chen, B, Jackisch, C, Untch, M, Perez, EA, Piccart-Gebhart, MJ & Viale, G 2014, 'Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study', Breast Cancer Research and Treatment, vol. 143, no. 3, pp. 485-492. https://doi.org/10.1007/s10549-013-2827-0
McCullough, Ann E. ; Dell'Orto, Patrizia ; Reinholz, Monica M. ; Gelber, Richard D. ; Dueck, Amylou ; Russo, Leila ; Jenkins, Robert Brian ; Andrighetto, Stefania ; Chen, Beiyun ; Jackisch, Christian ; Untch, Michael ; Perez, Edith A. ; Piccart-Gebhart, Martine J. ; Viale, Giuseppe. / Central pathology laboratory review of HER2 and ER in early breast cancer : An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. In: Breast Cancer Research and Treatment. 2014 ; Vol. 143, No. 3. pp. 485-492.
@article{0eadbfb670ec43da80301c17c4955b8d,
title = "Central pathology laboratory review of HER2 and ER in early breast cancer: An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study",
abstract = "Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status. Before randomization in the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN, and Scottsdale, AZ) for North America and by the European Institute of Oncology (IEO; Milan, Italy) for the rest of world (except China). Discordance rates (local vs. central review) differed between Mayo and IEO. Among locally HER2-positive cases, 5.8 {\%} (Mayo) and 14.5 {\%} (IEO) were centrally HER2 negative. Among locally ER-positive cases, 16.2 {\%} (Mayo) and 4.2 {\%} (IEO) were centrally ER-negative. Among locally ER-negative cases, 3.4 {\%} (Mayo) and 21.4 {\%} (IEO) were centrally ER-positive. We, therefore, performed a ring study to identify features contributing to these differing discordance rates. Mayo and IEO exchanged slides for 25 HER2 and 35 ER locally/centrally discordant cases. Both laboratories performed IHC and FISH for HER2 using the HercepTest{\circledR} and PathVysion HER2 DNA probe kit/HER2/centromere 17 probe mixture. IHC for ER was tested centrally using the monoclonal ER 1D5 antibody (Mayo) or the DAKO cocktail of ER 1D5 and 2.123 antibodies (IEO). Mayo and IEO confirmed the central HER2-negative result in 100 {\%} of 25 cases. Mayo and IEO confirmed the central ER result in 29 (85 {\%}) of 34 evaluable cases. The five Mayo-negative/IEO-positive cases were ER-positive when retested at Mayo using the DAKO ER cocktail. In this ring study, ALTTO ineligibility did not change when HER2 testing was performed by either IEO or Mayo central laboratories. However, a dual antibody ER assay had fewer false-negative test results than an assay with a single antibody, and there was more discordance between the two ER reagents than has been previously reported. Using even slightly different assay methods yielded different results, even between experienced central laboratories.",
keywords = "Breast cancer, Central laboratory review, Estrogen receptor testing, HER2 testing, Local versus central laboratory concordance",
author = "McCullough, {Ann E.} and Patrizia Dell'Orto and Reinholz, {Monica M.} and Gelber, {Richard D.} and Amylou Dueck and Leila Russo and Jenkins, {Robert Brian} and Stefania Andrighetto and Beiyun Chen and Christian Jackisch and Michael Untch and Perez, {Edith A.} and Piccart-Gebhart, {Martine J.} and Giuseppe Viale",
year = "2014",
month = "2",
doi = "10.1007/s10549-013-2827-0",
language = "English (US)",
volume = "143",
pages = "485--492",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Central pathology laboratory review of HER2 and ER in early breast cancer

T2 - An ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

AU - McCullough, Ann E.

AU - Dell'Orto, Patrizia

AU - Reinholz, Monica M.

AU - Gelber, Richard D.

AU - Dueck, Amylou

AU - Russo, Leila

AU - Jenkins, Robert Brian

AU - Andrighetto, Stefania

AU - Chen, Beiyun

AU - Jackisch, Christian

AU - Untch, Michael

AU - Perez, Edith A.

AU - Piccart-Gebhart, Martine J.

AU - Viale, Giuseppe

PY - 2014/2

Y1 - 2014/2

N2 - Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status. Before randomization in the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN, and Scottsdale, AZ) for North America and by the European Institute of Oncology (IEO; Milan, Italy) for the rest of world (except China). Discordance rates (local vs. central review) differed between Mayo and IEO. Among locally HER2-positive cases, 5.8 % (Mayo) and 14.5 % (IEO) were centrally HER2 negative. Among locally ER-positive cases, 16.2 % (Mayo) and 4.2 % (IEO) were centrally ER-negative. Among locally ER-negative cases, 3.4 % (Mayo) and 21.4 % (IEO) were centrally ER-positive. We, therefore, performed a ring study to identify features contributing to these differing discordance rates. Mayo and IEO exchanged slides for 25 HER2 and 35 ER locally/centrally discordant cases. Both laboratories performed IHC and FISH for HER2 using the HercepTest® and PathVysion HER2 DNA probe kit/HER2/centromere 17 probe mixture. IHC for ER was tested centrally using the monoclonal ER 1D5 antibody (Mayo) or the DAKO cocktail of ER 1D5 and 2.123 antibodies (IEO). Mayo and IEO confirmed the central HER2-negative result in 100 % of 25 cases. Mayo and IEO confirmed the central ER result in 29 (85 %) of 34 evaluable cases. The five Mayo-negative/IEO-positive cases were ER-positive when retested at Mayo using the DAKO ER cocktail. In this ring study, ALTTO ineligibility did not change when HER2 testing was performed by either IEO or Mayo central laboratories. However, a dual antibody ER assay had fewer false-negative test results than an assay with a single antibody, and there was more discordance between the two ER reagents than has been previously reported. Using even slightly different assay methods yielded different results, even between experienced central laboratories.

AB - Choice of therapy for breast cancer relies on human epidermal growth factor receptor-2 (HER2) and estrogen receptor α (ER) status. Before randomization in the phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial for HER2-positive disease, HER2 and ER were centrally reviewed by Mayo Clinic (Rochester, MN, and Scottsdale, AZ) for North America and by the European Institute of Oncology (IEO; Milan, Italy) for the rest of world (except China). Discordance rates (local vs. central review) differed between Mayo and IEO. Among locally HER2-positive cases, 5.8 % (Mayo) and 14.5 % (IEO) were centrally HER2 negative. Among locally ER-positive cases, 16.2 % (Mayo) and 4.2 % (IEO) were centrally ER-negative. Among locally ER-negative cases, 3.4 % (Mayo) and 21.4 % (IEO) were centrally ER-positive. We, therefore, performed a ring study to identify features contributing to these differing discordance rates. Mayo and IEO exchanged slides for 25 HER2 and 35 ER locally/centrally discordant cases. Both laboratories performed IHC and FISH for HER2 using the HercepTest® and PathVysion HER2 DNA probe kit/HER2/centromere 17 probe mixture. IHC for ER was tested centrally using the monoclonal ER 1D5 antibody (Mayo) or the DAKO cocktail of ER 1D5 and 2.123 antibodies (IEO). Mayo and IEO confirmed the central HER2-negative result in 100 % of 25 cases. Mayo and IEO confirmed the central ER result in 29 (85 %) of 34 evaluable cases. The five Mayo-negative/IEO-positive cases were ER-positive when retested at Mayo using the DAKO ER cocktail. In this ring study, ALTTO ineligibility did not change when HER2 testing was performed by either IEO or Mayo central laboratories. However, a dual antibody ER assay had fewer false-negative test results than an assay with a single antibody, and there was more discordance between the two ER reagents than has been previously reported. Using even slightly different assay methods yielded different results, even between experienced central laboratories.

KW - Breast cancer

KW - Central laboratory review

KW - Estrogen receptor testing

KW - HER2 testing

KW - Local versus central laboratory concordance

UR - http://www.scopus.com/inward/record.url?scp=84894073975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894073975&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2827-0

DO - 10.1007/s10549-013-2827-0

M3 - Article

C2 - 24395109

AN - SCOPUS:84894073975

VL - 143

SP - 485

EP - 492

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -